Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Dealing with the remaining controversies of probiotic safety.
Benef Microbes
July 2019
Athena Institute, VU Amsterdam, De Boelelaan 1085, 1081 HV, Amsterdam, the Netherlands.
A clear safety profile of probiotics in clinical practice is essential in decision-making for all stakeholders and regulators. Probiotics have been investigated in different target populations, conditions and age groups. This also includes the use of probiotics in critically ill patients.
View Article and Find Full Text PDFProbiotic, prebiotic, and synbiotic use in critically ill patients.
Curr Opin Crit Care
April 2012
Nebraska and Western Iowa Veterans' Affairs Hospital, Omaha, Nebraska, USA.
Purpose Of Review: To summarize the existing data regarding the use of probiotics, prebiotics, and synbiotics in select disorders encountered in the intensive care unit setting.
Recent Findings: Recent systematic reviews and meta-analyses have more rigorously aggregated the fragmented primary data which suffers from multiple limitations.
Summary: Probiotics are living microorganisms which, when ingested in adequate amounts, provide health benefits to the host.
Synbiotics and probiotics in the critically ill after the PROPATRIA trial.
Curr Opin Clin Nutr Metab Care
March 2012
Division of Pulmonary, Critical Care and Sleep Medicine, Nebraska, USA.
Purpose Of Review: Recent clinical trials have furthered our understanding of the role of probiotic and synbiotic therapy across a variety of diverse diseases including antibiotic-associated diarrhea, Clostridium difficile associated diarrhea, acute pancreatitis, ventilator-associated pneumonia, and sepsis among others. Although each of these conditions has implications for critically ill patients, relatively few studies have specifically studied this vulnerable population.
Recent Findings: One recent clinical trial studying probiotics in severe pancreatitis (the PROPATRIA trial) found an unexpected increase in mortality in probiotic-treated patients.
[PROPATRIA and safety in clinical trials. Comments on the IGZ-CCMO-VWA-raport].
Ned Tijdschr Geneeskd
February 2010
Academisch Medisch Centrum - Universiteit van Amsterdam, afd. Cardiologie, Amsterdam, The Netherlands.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!